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Background: The endovascular approach of ablation of renal sympathetic nerves is found to
be effective in the treatment of uncontrolled hypertension. We report here our experience
with the procedure in eight patients with drug resistant hypertension.
Methods: We included patients in whom the blood pressure remained above 150/90 mmHg
despite being on minimum three antihypertensive drugs. Radiofrequency ablation of the
sympathetic nerves of both the renal arteries was done using conventional ablation
catheters. The patients were followed at 1-month, 3 months and 6 months post procedure
and blood pressure recorded.
Results: All patients underwent successful renal sympathetic denervation. The mean blood
pressure of the patients was 181/102.5 mmHg before the procedure and the average
requirement of antihypertensive drugs per day was 4. A significant reduction in both
systolic and diastolic blood pressure was observed post procedure which sustained over
the follow up period of six months. The mean blood pressure observed at 1-month, 3 and 6
months were 137.5/80 mmHg, 136/81 mmHg and 137.5/81 mmHg, respectively. The average
requirement of the number of antihypertensives also was reduced to 2.5 at the end of 6
months. There were no procedural complications.
Conclusion: Catheter based renal denervation causes substantial and sustained blood
pressure reduction without serious adverse events in patients with resistant hypertension.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction remains uncontrolled despite the concurrent use of 3 or moreDespite the availability of an array of potent pharmacological
agents for the treatment of hypertension, resistant hyper-
tension (RH) continues to be a therapeutic challenge for
physicians. RH is defined as “blood pressure (BP) thatC. Narasimhan).
2013, Cardiological Societantihypertensive agents of different classes including a
diuretic prescribed in optimal doses”.1 Blood pressure that
gets controlled with the use of four or more medications is
also categorized as RH. The prevalence of true RH is estimated
to be around 5%.2,3 These patients carry a two to three fold risky of India. All rights reserved.
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tions compared to those hypertensives in whom BP is easily
manageable.4e6 Apart from drug intolerance, patient non-
compliance and non-adherence to lifelong drug therapy and
other lifestyle modifications are additional challenges in the
treatment of RH. Recently, catheter based ablation of renal
sympathetic nerves has emerged as a novel therapeutic op-
tion for this sub-set of patients.
Renal sympathetic denervation (RDN), by targeting the
renal nerves, cuts the crucial link between sympathetic ner-
vous system activation and hypertension. This endovascular
approach using a dedicated catheter (Simplicity) has been
proven to be safe and efficacious in clinical studies including a
randomized trial.7e11 In this procedure, a catheter connected
to a radiofrequency (RF) generator is used to cause sympa-
thetic denervation which is achieved percutaneously through
the lumen of the main renal artery. We report here our
experience with this procedure using conventional radio-
frequency ablation catheters in eight patients with RH.T
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y2. Methods
The study was done with the approval of the institutional
ethics committee. Consecutive 18 patients from August 2011
till June 2012 with RH who consented for the RDN procedure
were screened for eligibility. Patients whose average BP
recording was 150/90 or more (on at least 3 antihypertensives)
on 24 h BP monitoring were considered for the study. Further
eligibility was confirmed after renal angiogram. Patients who
were found to have renal artery stenosis or unsuitable renal
anatomy for the procedure were excluded from the study.
Patients who had deranged renal parameters but not on renal
dialysis, those who had valvular heart disease, female pa-
tients who were pregnant or were planning for pregnancy,
patients with history of renal artery intervention and those
with history of coronary syndrome or cerebrovascular acci-
dent within the preceding six months were also excluded.
Renal angiogram was done using the right femoral
approach and in thosewho had suitable renal artery, RDNwas
done using radiofrequency catheter ablation.
2.1. Renal denervation procedure
A 6F deflectable CELSIUS Thermistor (Biosense Webster,
Diamond Bar, CA, USA) conventional RF ablation catheter was
advanced into the renal arteries through Mullins sheath. A
Stockert RF generator was used to deliver RF energy in uni-
polar mode. We delivered RF energy for 60e90 s each and of
8e12 W and created 5e6 focal lesions, longitudinally sepa-
rated along the length of each renal artery. The cut off point
was taken as a reduction in impedance by 10%. The catheter
tip impedance was monitored continuously. RF delivery was
stopped if there was rise in impedance by more than 5 U.
Post procedure renal angiogram was done to assess for pro-
cedural complications within the renal arteries. Patients were
discharged on second post procedure day. A complete physical
examination including 24 h ambulatory BP monitoring, drug
compliance and renal profile which were assessed at baseline
were repeated at one, three and six months post RDN.
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Fig. 2 e Change in diastolic BP from baseline to six months
post RDN.
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Of the 18 patients screened, eight qualified the inclusion
and exclusion criteria. The BP was uncontrolled (mean 181/
102 mmHg) in all the patients despite being on maximum
tolerated doses of antihypertensive drugs for more than six
months. Baseline characteristics and clinical profile of the
patients are given in Table 1.
All patients underwent the RDN procedure successfully.
Within 48e72 h following the procedure, we observed a sig-
nificant drop in BP (mean 130/80 mmHg) which stabilized
later. The duration of the procedure averaged 40 min. This
reduction of BP was observed in all the eight patients and
sustained over followup period (Figs. 1 and 2). At the end of six
months post RDN, we observed a reduction of 24% of systolic
and 20.7% of diastolic BP.
There were no procedure related complications. Renal
functionswere unaffected as evidenced by the unaltered renal
parameters post procedure.4. Discussion
It is known that sympathetic nervous system (SNS) plays a
vital role in the initiation and maintenance of high blood
pressure (11). The degree of SNS activation correlates with the
severity of hypertension. Overdrive of SNS has also been
found to be associated with target-organ damage associated
with chronic hypertension.12 Before the advent of pharma-
cological agents, surgical approaches were used to directly
target the SNS for hypertension control using procedures like
splanchnicectomy and radical sympathectomy. Though effi-
cient in BP reduction, the safety aspect was severely
compromised in these procedures as the renal arteries were
not selectively targeted. The response of kidney to SNS
signaling is considered as one important mechanism which
raises BP. The renal sympathetic stimulation increases renin
secretion, reduces urinary sodium excretion and induces
vasoconstriction.12,13 Therefore, by specifically targeting the
renal efferent sympathetic and sensory afferent signaling, it
was considered possible to achieve BP reductions with
reasonable safety which was not possible with the earlier100
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Fig. 1 e Change in systolic BP from baseline to six months
post RDN.surgical approaches. The renal sympathetic nerves arise from
T10-L1 and enter the kidneys through the renal arteries and lie
within the adventitia, within easy reach for the delivery of
radiofrequency energy delivery. This relatively easy and se-
lective approachability of the renal nerves has brought renal
denervation back to focus.
In linewith the previously conducted studies,7e11 we found
that the catheter based RDN procedure using RF energy to be a
very effective and safe procedure. The RDN procedure ach-
ieved a significant reduction in both systolic and diastolic BP.
The mean reduction of office BP at the end of six months was
43.5/21 mmHg. The average number of antihypertensive
drugs was also reduced from four pre-procedure to two at the
end of six months post RDN. The procedure also had an
excellent short and intermediate safety profile. Renal angio-
gram immediately following the procedure did not show any
injury to the renal arteries. The procedure was found to be
effective in patients with chronic renal dysfunction also.
These patients continued to be on dialysis even after RDN
but their requirement of antihypertensive drugs was reduced.
Blood renal profile at the end of six months also remained
stable indicating normally functioning kidneys.5. Limitations
Our study is proof of concept study demonstrating the efficacy
and safety of conventional radiofrequency ablation catheter
for renal denervation. This study revealed that renal dener-
vation performed with the conventional radiofrequency
ablation catheter is effective and is likely to be less expensive.
In our study, we have notmonitored the GFR in chronic kidney
disease patients. The effect of renal denervation on renal
function in chronic kidney disease patients needs to be eval-
uated in randomized control trials. It should be emphasized
that medical therapy and lifestyle modifications should be
continued in these patients in spite of RDN therapy. However,
large randomized controlled studies using this technique will
be needed to prove the efficacy of this therapy.
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